Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors

Phase 1 Terminated 16 enrolled Washington University School of Medicine Xcovery Holdings, Inc. · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The investigators hypothesize that vorolanib in combination with checkpoint inhibitors (pembrolizumab for gastric/gastroesophageal (GE) junction cancers and nivolumab for hepatocellular carcinoma (HCC)) may improve immunotherapy efficacy by overcoming treatment resistance of checkpoint inhibitors in gastrointestinal (GI) cancers.

Timeline

Start: 2018-09-11
Primary completion: 2019-08-15
Completion: 2020-05-28

Publications

Bagegni NA, Park H, Kraft K, O-Toole M, Gao F, Waqar SN, Ratner L, Morgensztern D, Devarakonda S, Amin M, Baggstrom MQ, Liang C, Selvaggi G, Wang-Gillam A. Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2022 Apr;89(4):487-497. doi: 10.1007/s00280-022-04406-6. Epub 2022 Mar 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CM082	Unknown	300 mg	Oral
Subject	CM082	Unknown	400 mg	Oral
Subject	Nivolumab	Monoclonal antibody	480 mg	Intravenous
Subject	Pembrolizumab	Monoclonal antibody	200 mg	Intravenous

Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors

Summary

Timeline

Publications

Drugs

Indications